Clinical trials: Advanced Hepatocellular Carcinoma
Hepatitis B, Chronic
Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis
Chronic Hepatitis B infection (CHB) is known as the most frequently identified cause of liver disease that predisposes patients to the development of hepatocellular carcinoma (HCC).
- Trial name
- NCT02224456
- Testing
- Tenofovir disoproxil fumarate
- Where
- 19 sites in China
- Volunteers
- 197 people
- Sponsor
- GlaxoSmithKline
Hepatocellular Carcinoma
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
This is a Phase I, open-label, multi-center study to assess the safety, pharmacokinetics, and preliminary efficacy of GPC3-directed chimeric antigen receptor modified T cells injection (Ori-C101) in Advanced Hepatocellular…
- Trial name
- NCT05652920
- Testing
- Ori-C101
- Where
- 7 sites in China
- Volunteers
- 105 people
- Sponsor
- OriCell Therapeutics Co., Ltd.
Advanced or Unresectable Hepatocellular Carcinoma (HCC)
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
This is a randomized, open-label, multicenter Phase Ib/II registration trial designed to evaluate the efficacy and safety of HH-009 in patients with FGF19-positive hepatocellular carcinoma (HCC).
- Trial name
- NCT07547553
- Testing
- Will receive HH-009 injection 20 mg/kg, Q3W, Will receive HH-009 injection 30 mg/kg, Q3W
- Where
- 21 sites in China
- Volunteers
- 30 people
- Sponsor
- Huahui Health
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
The primary objective of this study was to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT04401800
- Testing
- Lenvatinib, Tislelizumab
- Where
- 9 sites in China
- Volunteers
- 64 people
- Sponsor
- BeiGene
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Hepatocellular Carcinoma (HCC)
A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
This is a Phase 2 study to evaluate the efficacy and safety of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced or unresectable FGF19-overexpressing hepatocellular carcinoma.
- Trial name
- NCT07239986
- Testing
- BB102
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Broadenbio Ltd., Co.
Hepatocellular Carcinoma
Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
The current understanding of PR104 justifies the evaluation of PR104 with sorafenib in patients with hepatocellular carcinoma. These include: Hypoxia.
- Trial name
- NCT00862082
- Testing
- PR104 550 mg/m^2 + sorafenib, PR104 770 mg/m^2 + sorafenib
- Where
- 17 sites in United States, Hong Kong and 2 more
- Volunteers
- 14 people
- Sponsor
- Proacta, Incorporated
Advanced Solid Tumors, Ewing Sarcoma
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
- Conditions
- Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07197554
- Testing
- ST-01156
- Where
- 6 sites in United States
- Volunteers
- 171 people
- Sponsor
- SEED Therapeutics, Inc.
Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma
A single-arm, open-label clinical trial, focus on the safety and efficacy of TQB2450 injection combined with Anlotinib hydrochloride capsule in patients with advanced biliary adenocarcinoma/hepatocellular carcinoma
- Trial name
- NCT03825705
- Testing
- TQB2450 injection, Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Carcinoma, Hepatocellular
Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
The study aim is to determine maximally tolerated dose (MTD) of BIBF 1120 in HCC (hepatocellular cancer) and compare efficacy of BIBF 1120 to Sorafenib in HCC patients
- Trial name
- NCT01004003
- Testing
- Sorafenib, BIBF 1120
- Where
- 28 sites in Austria, France and 6 more
- Volunteers
- 125 people
- Sponsor
- Boehringer Ingelheim
Advanced Hepatocellular Carcinoma
A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of cabozantinib in Japanese participants with advanced hepatocellular carcinoma (HCC) who have received prior systemic anticancer therapy.
- Trial name
- NCT03586973
- Testing
- Cabozantinib
- Where
- 17 sites in Japan
- Volunteers
- 34 people
- Sponsor
- Takeda
Hepatocellular Carcinoma
Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma
This was a Phase 2 trial composed of an open label Lead-In followed by a planned Randomized Phase designed to evaluate the efficacy and safety of SRF388 in combination with atezolizumab plus bevacizumab compared to placebo…
- Trial name
- NCT05359861
- Testing
- Casdozokitug, Atezolizumab, Bevacizumab
- Where
- 37 sites in United States, Australia and 2 more
- Volunteers
- 30 people
- Sponsor
- Coherus Oncology, Inc.
NSCLC, Prostate Cancer
Clinical Trial of TB511 in Advanced Solid Tumors
1. Study population [TB511 Monotherapy Cohort for Phase 1 and Phase 2a Clinical Trial] Patients with advanced solid tumors who are either refractory or intolerant to standard of care (SoC).
- Conditions
- NSCLC, Prostate Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06400160
- Testing
- TB511, Keytruda
- Volunteers
- 12 people
- Sponsor
- Twinpig Biolab, Inc.
Hepatocellular Carcinoma
Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma
This study will evaluate the safety, efficacy, and activity of patupilone in patients with advanced unresectable and/or metastatic hepatocellular carcinoma based on tumor response using modified RECIST criteria.
- Trial name
- NCT00273312
- Testing
- Patupilone
- Where
- 7 sites in United States, Hong Kong and 2 more
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours…
- Trial name
- RHEA-1 (NCT06795022)
- Testing
- AZD9793 Intravenous (IV) monotherapy, AZD9793 Subcutaneous (SC) monotherapy
- Where
- 21 sites in United States, China and 5 more
- Volunteers
- 304 people
- Sponsor
- AstraZeneca
Solid Tumors, Non Small Cell Lung Cancer
BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
The goal of this first in human clinical trial is to test BI-1910 administered as single agent and in combination with pembrolizumab in subjects with advanced/metastatic solid tumors whose disease has progressed after standard…
- Conditions
- Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06205706
- Testing
- BI-1910, Pembrolizumab
- Where
- 8 sites in Denmark, Germany and 2 more
- Volunteers
- 35 people
- Sponsor
- BioInvent International AB
Hepatocellular Carcinoma
Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine maximum tolerated dose (MTD), efficacy, safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor effect of E7080 when is administered continually once daily in…
- Trial name
- NCT00946153
- Testing
- Lenvatinib
- Where
- 12 sites in Japan, South Korea
- Volunteers
- 66 people
- Sponsor
- Eisai Co., Ltd.
Advanced Solid Tumors, Hepatocellular Carcinoma
A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma
This is an open-label, multicenter, phase 1 dose escalation study of BBI503 monotherapy, or BBI503 in combination with Sorafenib.
- Trial name
- NCT02354898
- Testing
- BBI503, Sorafenib
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Advanced Hepatocellular Carcinoma
Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC
"Immuncell-LC" in aspects of therapeutic efficacy and safety when administered with Nexavar to advanced Hepatocellular carcinoma patients when compared with the control group who did not receive administration of the drug.
- Trial name
- NCT01897610
- Testing
- Immuncell-LC
- Where
- 4 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- GC Cell Corporation
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.